Evaluation of Safety and Efficacy of a Single Lorecivivint Injection in Patients with Knee Osteoarthritis: A Multicenter, Observational Extension Trial.

Patient Global Assessment Changes from Baseline The unilateral mITT analysis set treated with LOR 0.07 mg showed statistically significant improvements in change from baseline in PtGA compared to PBO at month 3 (treatment difference estimate of − 11.35, 95% CI [(− 18.87, − 3.82)], P = 0.003); these changes approached but did not reach statistical significance at month 6 (treatment difference estimate of − 7.52, 95% CI [(− 15.16, 0.12)], P = 0.054)) and were not significant at month 18 (treatment difference estimates of − 2.94, 95% CI [(− 10.97, 5.09)], P = 0.470).

also in 111,027 other papers